Expanding the Pool in Orthotopic Heart Transplantation

Completed · Phase 2

Conditions studied: Hepatitis C, Heart Transplant, Cardiac Transplant

In brief

This is an open-label, pilot trial to test the safety and efficacy of transplantation of hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on the heart transplant waitlist. Treatment and prophylaxis will be administered, using a transmission-triggered approach for the first scenario (HCV Ab+/NAT- donors, arm 1) and a prophylaxis approach for the later scenario (HCV Ab+/NAT+ donors, arm 2).

Key facts

Study ID
NCT03222531
Run by
Mary E. Keebler, MD
People needed
20
Starts
2017-08-01
Expected to finish
2026-06-02
Last updated by the study team
2026-06-22

Who can join

Age: 18 and older, up to 71. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.